Besides ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit sufficient to tolerate FCR therapy, should be very good candidates to the latter, Together with the reward getting that this cure is often accomplished in 6 months even though ibrutinib have to be taken indefinitely. This fe